These studies demonstrate the potential of identifying key regulators in cancer immune escape mechanisms to open the avenue for developing novel therapies, which could complement standard immune checkpoint inhibitors targeting CTLA-4 or PD-1 or other therapeutic agents. The gene discussed is CTLA4; the disease is cancer.